Evidence map›Paper›PMID 40971062›Full record

ArticleOphthalmology and therapy2025

Early Outcome Analysis of Intravitreal Aflibercept 8 mg Treatment in Naïve Patients with Neovascular Age-Related Macular Degeneration Using Artificial Intelligence.

Nicolò Bartolomeo, Yannic Pannatier Schuetz, Anna Chiara Nascimbeni, Daniela Gallo Castro, Baptiste Crozat, Mamadou Pathé Barry, Aude Ambresin

Abstract read
In one paragraph

Article in Ophthalmology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Nicolò BartolomeoSwiss Visio Retina Research Center, Swiss Visio Montchoisi, Lausanne, Switzerland.
Yannic Pannatier SchuetzSwiss Visio Retina Research Center, Swiss Visio Montchoisi, Lausanne, Switzerland.
Anna Chiara NascimbeniSwiss Visio Retina Research Center, Swiss Visio Montchoisi, Lausanne, Switzerland.
Daniela Gallo CastroSwiss Visio Retina Research Center, Swiss Visio Montchoisi, Lausanne, Switzerland.
Baptiste CrozatSwiss Visio Retina Research Center, Swiss Visio Montchoisi, Lausanne, Switzerland.
Mamadou Pathé BarrySwiss Visio Retina Research Center, Swiss Visio Montchoisi, Lausanne, Switzerland.
Aude AmbresinSwiss Visio Retina Research Center, Swiss Visio Montchoisi, Lausanne, Switzerland. aambresinsvrrc@swissvisio.net.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionNeovascular age-related macular degeneration (nAMD) is one of the leading causes of vision loss, often requiring frequent injections. Our aim is to report the early outcomes of intravitreal aflibercept (IVA) 8 mg treatment in naïve patients with nAMD.

methodsAn observational, retrospective, monocentric study was conducted at Swiss Visio Montchoisi, Lausanne, Switzerland. A total of 51 eyes of 48 patients with naïve macular neovascularization (MNV) secondary to AMD received a loading phase of three-monthly IVA followed by a monthly observational phase until fluid recurrence. At each visit, all patients had a full ophthalmological exam, including spectral-domain optical coherence tomography (SD-OCT), which was analysed manually and with artificial intelligence (AI). The main outcomes were best-corrected visual acuity (BCVA), central subfield thickness (CST), maximal pigment epithelial detachment (PED) height, presence or absence of intraretinal fluid (IRF) and subretinal fluid (SRF) on SD-OCT, and mean volumetric changes in IRF, SFR, and PED using AI at baseline and month 1, 2, 3, and 6.

resultsMean age at baseline was 79.94 ± 7.29 years, and 81.25% of patients were female. At baseline, mean BCVA was 70.44 ± 12.48 Early Treatment Diabetic Retinopathy Study (ETDRS) letters, mean CST was 339.8 ± 174.6.0 μm, and mean Maximal PED height was 214.3 ± 115.1 μm. After loading and at month 6, BCVA significantly increased by 2.47 and 3.41 ETDRS letters, respectively. Mean CST and PED height significantly decreased to 231.9 ± 68.69 μm and 137.6 ± 68.53 μm, respectively, at month 6. Qualitative and AI-quantified biomarkers significantly decreased after loading and at month 6. A mean interval of 9.67 ± 3.87 weeks was reached with a mean number of 4.63 ± 1.01 injections at the time of the last observation. Baseline IRF and HRF were negative predictors of functional outcomes in the short term. One patient with sterile vitritis benefited from vitrectomy and topical treatment.

conclusionsAflibercept intravitreal injections in the treatment of naïve patients with wet AMD demonstrated rapid improvement of functional and anatomical parameters, particularly regarding fluid control and quantitative biomarkers on OCT. A comprehensive analysis of follow-up visits will be performed to confirm our early results.

Indexed as

Aflibercept 8 mgAI-based analysisArtificial intelligenceFluid dynamicsNaïvenAMDOCT biomarkersPredictionsTreatment outcomes

Identifiers

PMID40971062
PMCPMC12534677

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.